Biogen completes $41-per-share acquisition of Apellis Pharmaceuticals, gaining nephrology infrastructure and complement-targeted therapies including SYFOVRE and

Cue Biopharma pivots to anti-IgE and autoimmunity programs after securing $7.5M milestone from Boehringer Ingelheim and $30M private placement.

Telix announces PSMA-PET collaborations with EDAP TMS and Profound Medical to integrate imaging into prostate cancer ablation workflows.

Eton Pharmaceuticals posts 73% Q1 revenue growth and raises 2026 guidance by $10M, driven by newly launched rare disease...

Senti Biosciences advances SENTI-202 to pivotal trial in relapsed AML with FDA endorsement of single-arm design and 50% composite...

Citius Oncology reports $5.6M Q2 revenue for LYMPHIR launch with near-100% commercial coverage and 80% gross margins despite cash...

Biogen acquires Apellis Pharmaceuticals for $41 per share in a $689M deal focused on building nephrology infrastructure for felzartamab,...

Regeneron's Phase 3 fianlimab trial misses in first-line melanoma, threatening a key pipeline asset and handing Opdualag a competitive...

Cue Biopharma raises $30M and shifts focus to immunology pipeline, exiting oncology with two new assets including a late-stage...

Pelthos Q1 2026 ZELSUVMI revenue reaches $10.7M with 17% sequential growth as the company plans multi-product dermatology expansion.